- luka.tandaric@uib.no
- Phone number
- +47 4830 2929
- Visitor address
-
Haukeland universitetssykehus, Laboratoriebygget
5009 Bergen - Postal address
-
P.O. Box 7804NO-5020 BergenNorway
Publications
Academic article
- Benjamin William Caulier; Sandy Joaquina; Pascal Francois Gelebart et al. (2024). CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. (external link)
- M.R. Mirza; Luka Tandaric; J.R. Henriksen et al. (2024). NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer. (external link)
- Luka Tandaric; Annika Auranen; Katrin Kleinmanns et al. (2025). Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial. (external link)
- Leo Meriranta; Selma Sorri; Kanutte Huse et al. (2024). Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma. (external link)